David A. Siegel I Mab Transaction History
Two Sigma Advisers, LP
- $46.1 Billion
- Q2 2025
A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in I Mab stock. As of the latest transaction made, Two Sigma Advisers, LP holds 209,383 shares of IMAB stock, worth $806,124. This represents 0.0% of its overall portfolio holdings.
Number of Shares
209,383
Previous 363,200
42.35%
Holding current value
$806,124
Previous $297,000
70.37%
% of portfolio
0.0%
Previous 0.0%
Shares
14 transactions
Others Institutions Holding IMAB
# of Institutions
40Shares Held
14.2MCall Options Held
10.2KPut Options Held
0-
Hhlr Advisors, Ltd. Grand Cayman, E95.98MShares$23 Million0.6% of portfolio
-
Decheng Capital Management Iii (Cayman), LLC4.17MShares$16 Million3.04% of portfolio
-
Candriam S.C.A.1.13MShares$4.36 Million0.02% of portfolio
-
Sg Americas Securities, LLC876KShares$3.37 Million0.01% of portfolio
-
International Biotechnology Trust PLC London, X0310KShares$1.2 Million0.14% of portfolio
About I-Mab
- Ticker IMAB
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 83,098,800
- Market Cap $320M
- Description
- I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics to treat cancer and autoimmune disorders. It is developing Felzartamab, a CD38 antibody that is in Phase 1b/2a for patients with membranous nephropathy; Eftansomatropin alfa, a long-acting human growth hormone, which has completed Phase 3 clinica...